BC Tech And Genome BC Team Up To Nurture Life Sciences Entrepreneurs

May 23, 2018

VANCOUVER, 22 May, 2018 – Today, HyperGrowth: Life celebrates the graduation of its second cohort — a group that promises to change the way we live, work and play with breakthroughs at the intersection of technology and the life sciences. Recognizing the tremendous potential that exists within the life sciences, in 2016 the BC Tech … Continue reading BC Tech And Genome BC Team Up To Nurture Life Sciences Entrepreneurs

DelMar Appoints Saiid Zarrabian to Full-Time President and CEO

May 22, 2018
Delmar Pharmaceuticals Inc

VANCOUVER, British Columbia and MENLO PARK, Calif., May 22, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (the “Company”)(NASDAQ: DMPI) today announced that the board of directors (the “Board”) has appointed Saiid Zarrabian as the full-time President and Chief Executive Officer of the Company, effective immediately. Mr. Zarrabian had previously served as the Company’s interim President and … Continue reading DelMar Appoints Saiid Zarrabian to Full-Time President and CEO

Global Health Sciences Fund invests 10 M USD in Canary Medical’s proprietary, “smart” implant technology designed to improve outcomes in post-surgical patients

May 18, 2018
Canary Medical Inc.

The Canary Health Implantable Reporting Processor (CHIRP) uses innovative sensor and novel communication technology in medical devices to enable remote patient monitoring. “Smart” medical devices will self-report on everything from patient activity to recovery and even treatment failure, without the need for physician intervention or a dependence upon patient compliance. Vancouver, British Columbia – May … Continue reading Global Health Sciences Fund invests 10 M USD in Canary Medical’s proprietary, “smart” implant technology designed to improve outcomes in post-surgical patients

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results

DelMar Pharmaceuticals, Inc.

Company will host a business update conference call on May 30, 2018 at 4:30 PM Eastern Time VANCOUVER, British Columbia and MENLO PARK, Calif., May, 17, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the … Continue reading DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results

Application for CDRD / Pfizer Canada Life Sciences Executive Institute Now Open

May 17, 2018
CDRD, Phizer Canada

On May 2, CDRD, Canada’s national drug development and commercialization centre, and Pfizer Canada announced the launch of  the CDRD Executive Institute under the umbrella of The CDRD Academy – made possible by a significant $1,000,000 contribution by Pfizer Canada. The Institute’s aim is to provide ongoing executive development to ensure that the Canadian life sciences … Continue reading Application for CDRD / Pfizer Canada Life Sciences Executive Institute Now Open

Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference

May 16, 2018
Xenon

Company to Hold Conference Call at 8:00 am ET Today XEN1101 Pilot TMS-EEG Data Demonstrates Statistically Significant Effect of 20mg Dose versus Baseline (p<0.01) and Greater Effect on TMS-EMG Resting Motor Threshold at Significantly Lower Dose When Compared to Ezogabine Phase 1 Pharmacokinetic Data Supports Potential for Once Daily Dosing   BURNABY, British Columbia, May … Continue reading Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference

Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference

Xenon Pharmaceuticals Inc

  Company to Hold Conference Call at 8:00 am ET Today Preliminary Phase 1 Clinical Data Support Drug Exposure Levels Higher than Required in Pre-clinical Efficacy Models with Excellent Tolerability and Safety New Pre-clinical Data Support Selective Nav1.6 Mechanism of Action and XEN901 Efficacy Superior to Standard of Care Sodium Channel Blockers   BURNABY, British … Continue reading Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference

Aquinox to Present at 2018 UBS Global Healthcare Conference

Aquinox Pharmaceuticals

VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 2018 UBSGlobal Healthcare Conference in New York … Continue reading Aquinox to Present at 2018 UBS Global Healthcare Conference

LSBC Congratulates Sue Paish on her Appointment to CEO of BC Digital Supercluster Initiative

BC Digital Supercluster

VANCOUVER, BC – May 16, 2018 – LifeSciences BC President and CEO, Dr. Lesley Esford and Board of Director’s Chair, Nancy Harrison, are pleased to congratulate Sue Paish on her appointment as CEO of the Digital Technology Supercluster. In her new role Paish will be responsible for building and leading the digital supercluster initiative based … Continue reading LSBC Congratulates Sue Paish on her Appointment to CEO of BC Digital Supercluster Initiative